Novo Nordisk (NYSE:NVO) shares are rallying 6.87% to $86.67 as of 10:27 AM ET Friday, after the company reported promising trial results for its new obesity drug, amycretin.
In a Phase 1b/2a trial, amycretin led to up to 22% weight loss over 36 weeks, showing a safety profile similar to Novo's semaglutide and Eli Lilly's (NYSE:LLY) tirzepatide. The 125-subject study evaluated the drug's safety, tolerability, and effectiveness in overweight and obese individuals. Patients taking 1.25 mg for 20 weeks lost 9.7% of their weight, those on 5 mg for 28 weeks lost 16.2%, and the 20 mg group at 36 weeks saw 22% weight loss.
Meanwhile, those in the placebo group gained between 1.9% and 2.3%. Novo also tested an oral version of amycretin last year, showing similar weight-loss effects. Martin Lange, Novo's head of drug development, said the results reinforce amycretin's potential as a next-generation obesity treatment.
This article first appeared on GuruFocus.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.